| 摘要 |
Dyskinesias in humans are treated by administering a therapeutically effective dose of an NR1A/2B site-selective NMDA receptor antagonist compound to a human suffering therefrom. Ar1 and Ar2 are independently aryl or a heteroaryl group, either of which may be independently substituted by one to three of hydroxy, alkyl, halogen, nitro, cyano, carboxaldehyde, aldehyde oxime, lower alkoxy carbonylmethyl, acetamido, aryl, aralkyl, amino, a halogenated alkyl group, a lower alkyl amino group or a lower alkoxy group; X is (CHR3)m-, where in each R3 is independently hydrogen, hydroxy or a lower alkyl group having 1 to 6 carbon atoms; and m is 0 or 1; each r2 is independently hydrogen, hydroxy or a lower alkyl group having 1 to 6 carbon atoms; n is 1 or 2; Y is C C, O, SOp wherein p is 0, 1 or 2, NR4 wherein R4 is hydrogen or a lower alkyl group having 1 to 6 carbon atoms or a single bond. R5 is hydrogen or hydroxyl; and provided Ar2 is substituted by at least one of hydroxyl, alkyl, halogen, nitro, cyano, carboxaldehyde, aldehyde oxime, lower alkoxy carbonylmethyl, hydroxyl lower alkyl, aminocarbonylmethyl, hydrazinocarbonylmethyl, acetamido, aryl, aralkyl, amino, a halogenated alkyl group, a lower alkyl amino group or a lower alkoxy group.
|
